You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics, N = 88

From: Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort

Characteristic Patients
Sex  
• Male 57 (64.8%)
• Female 31 (35.2%)
Median Age [y] 51.0 (18 – 73)
• < 50 39 (44.3%)
• ≥ 50 49 (55.7%)
Median KPS 80 (40 – 100)
• KPS < 70 18 (20.5%)
• KPS ≥ 70 65 (73.9%)
• Unknown 5 (5.7%)
Median dose of primary radiotherapy 60 Gy
Median dose of re-irradiation 36 Gy
Time interval ≤ 12 months 29 (33%)
Time interval > 12 months 59 (67%)
Bevacizumab during re-irradiation  
• Yes 71 (80.7%)
• No 17 (19.3%)
MGMT methylation status  
• Methylated 42 (47.7%)
• not methylated 36 (40.9%)
• unknown 10 (11.4%)
Initial WHO grade  
• II 7 (8.0%)
• III 20 (22.7%)
• IV 61 (69.3%)
WHO grade at relapse  
• III 23 (26.1%)
• IV 65 (73.9%)
Concomitant TMZ treatment during first RT  
• Yes 68 (77.3%)
• No 20 (22.7%)
Chemotherapy  
• No adjuvant chemotherapy 36 (40.9%)
• Adjuvant therapy 45 (51.1%)
• Unknown 7 (8.0%)